87 related articles for article (PubMed ID: 10825142)
1. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma.
Wong CP; Levy R
Cancer Res; 2000 May; 60(10):2689-95. PubMed ID: 10825142
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.
Thirdborough SM; Radcliffe JN; Friedmann PS; Stevenson FK
Cancer Res; 2002 Mar; 62(6):1757-60. PubMed ID: 11912151
[TBL] [Abstract][Full Text] [Related]
3. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
4. TCR vaccines for active immunotherapy of T cell malignancies.
Okada CY; Wong CP; Denney DW; Levy R
J Immunol; 1997 Dec; 159(11):5516-27. PubMed ID: 9548492
[TBL] [Abstract][Full Text] [Related]
5. Maternal immunization with a soluble TCR-Ig chimeric protein: long term, V beta-8 family-specific suppression of T cells by maternally transferred antibodies.
McKeever U; Khandekar S; Jesson M; Newcomb J; Gregory P; Naylor J; Haskins K; Jones B
J Immunol; 1997 Dec; 159(12):5936-45. PubMed ID: 9550391
[TBL] [Abstract][Full Text] [Related]
6. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
8. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
9. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.
Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y
Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238
[TBL] [Abstract][Full Text] [Related]
11. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 against collagen-induced arthritis in rats.
Xiao J; Li S; Wang W; Li Y; Zhao W
Cell Mol Immunol; 2007 Dec; 4(6):439-45. PubMed ID: 18163955
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
[TBL] [Abstract][Full Text] [Related]
14. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
15. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adenovirus vaccines can successfully elicit CD8+ T cell immunity under conditions of extreme leukopenia.
Grinshtein N; Yang TC; Parsons R; Millar J; Denisova G; Dissanayake D; Leitch J; Wan Y; Bramson J
Mol Ther; 2006 Feb; 13(2):270-9. PubMed ID: 16297666
[TBL] [Abstract][Full Text] [Related]
17. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
18. Diversity and complexity of CD8+ T cell responses against a single epitope of adenovirus E1B.
Kim M; Kim K
Virology; 2002 Apr; 295(2):238-49. PubMed ID: 12033782
[TBL] [Abstract][Full Text] [Related]
19. T-cell immunity generated by recombinant adenovirus vaccines.
Yang TC; Millar JB; Grinshtein N; Bassett J; Finn J; Bramson JL
Expert Rev Vaccines; 2007 Jun; 6(3):347-56. PubMed ID: 17542750
[TBL] [Abstract][Full Text] [Related]
20. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
